Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review Mar 09, 2026

Show notes

Featuring an interview with Dr Hanny Al-Samkari, including the following topics:

VAYHIT1: A multicenter randomized, double-blind, Phase III trial evaluating ianalumab versus placebo in addition to first-line corticosteroids for patients with primary immune thrombocytopenia (ITP) (0:00)
Secondary analysis results from VAYHIT3, a Phase II study of ianalumab for patients with primary ITP previously treated with at least 2 lines of therapy (8:15)
Improved health-related quality of life and bleeding scores with the oral Bruton tyrosine kinase inhibitor rilzabrutinib in the open-label period of the multicenter Phase III LUNA 3 study for adults with ITP (12:23)
Romiplostim for chemotherapy-induced thrombocytopenia in patients with colorectal, gastroesophageal and pancreatic cancer: A global Phase III randomized, placebo-controlled trial (16:01)

CME information and select publications

Ovarian Cancer — Year in Review Series on Relevant New Datasets and Advances Mar 07, 2026

Show notes

Featuring perspectives from Prof Nicoletta Colombo and Dr Kathleen N Moore, including the following topics:

Introduction (0:00)
Promising Novel Agents and Strategies Under Investigation in Ovarian Cancer (2:35)
Current Management of Newly Diagnosed and Relapsed/Refractory Ovarian Cancer(41:48)

CME information and select publications

Ovarian Cancer | Nicoletta Colombo, MD Mar 06, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Ovarian Cancer | Faculty Presentation 2: Promising Novel Agents and Strategies Under Investigation in Ovarian Cancer — Nicoletta Colombo, MD

CME information and select publications

Ovarian Cancer | Angeles Alvarez Secord, MD, MHSc Mar 06, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Ovarian Cancer | Faculty Presentation 1: Current Management of Newly Diagnosed and Relapsed/Refractory Ovarian Cancer — Angeles Alvarez Secord, MD, MHSc

CME information and select publications

Oncology Nursing Update: Colorectal Cancer — An Interview with Dr Christopher Lieu on Molecular Residual Disease Analysis Mar 06, 2026

Show notes

Featuring an interview with Dr Christopher Lieu, including the following topics:

Historical approach to the adjuvant treatment of localized colorectal cancer (CRC) (0:00)
Perspectives on earlier-onset colorectal cancer and potential drivers; management of oligometastatic disease (13:16)
Overview of cell-free DNA (circulating tumor DNA [ctDNA]) and techniques for its measurement (17:03)
Reliability and prognostic capability of ctDNA as a biomarker for clinical status in patients with localized colorectal cancer (21:10)
ctDNA assessment and treatment decision-making for patients with Stage II colon cancer (26:38)
Potential incorporation of ctDNA assays into the management of metastatic colorectal cancer or microsatellite instability-high disease (34:29)
Available clinical data with ctDNA assessment in localized rectal cancer (38:54)
Current practice patterns with ctDNA assays for patients with localized colorectal cancer (41:17)
Case: A woman in her early 40s with resected lower risk Stage III colon cancer requests ctDNA testing (45:47)
Case: A man in his early 50s with Stage IIIB colon cancer wants to avoid adjuvant chemotherapy (50:39)
Case: A man in his early 60s with Stage IV colon cancer receives a positive postoperative ctDNA assessment result (53:24)

NCPD information and select publications

Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review Mar 03, 2026

Show notes

Featuring an interview with Dr Hanny Al-Samkari, including the following topics:

Mechanism of action and toxicity of the monoclonal antibody ianalumab (0:00)
Primary results from VAYHIT2, a randomized, double-blind Phase III trial of ianalumab with eltrombopag for patients with primary immune thrombocytopenia (ITP) after failure of first-line corticosteroid treatment (7:32)
Mechanism of action and toxicity of the Bruton tyrosine kinase inhibitor rilzabrutinib (11:52)
Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent or chronic ITP in the long-term extension period of the Phase III LUNA3 study (18:46)

CME information and select publications

Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances Mar 02, 2026

Show notes

Featuring perspectives from Dr Hope S Rugo and Dr Sara M Tolaney, including the following topics:

Introduction: Long-Term Outcomes with Antibody-Drug Conjugates (0:00)
HER2-Positive Breast Cancer (8:02)
HER2-Negative Breast Cancer (32:41)

CME information and select publications

Antibody-Drug Conjugates for Breast Cancer | Sara M Tolaney, MD, MPH Mar 01, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 2: Current and Emerging Role of TROP2-Directed ADCs — Sara M Tolaney, MD, MPH

CME information and select publications

Antibody-Drug Conjugates for Breast Cancer | Hope S Rugo, MD Feb 28, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 1: Current and Emerging Role of HER2-Directed Antibody-Drug Conjugates (ADCs) — Hope S Rugo, MD

CME information and select publications

Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy Feb 27, 2026

Show notes

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics:

Introduction: Rational Treatment Goals for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)? (0:00)
Current Considerations in the Selection of First-Line and Maintenance Therapy — Dr Borghaei (8:13)
Case: A woman in her early 60s newly diagnosed with ES-SCLC who receives first-line atezolizumab/EP and maintenance atezolizumab with delayed addition of lurbinectedin — Dr Borghaei (16:21)
Case: A woman in her mid 60s with multiple comorbidities newly diagnosed with ES-SCLC who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin with discontinuation of lurbinectedin — Dr Borghaei (23:46)
Clinician Survey Results (32:16)
Case: A woman in her early 70s with multiple comorbidities and newly diagnosed ES-SCLC with TP53 and RB1 mutations who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin — Dr Chiang (41:39)
Case: A man in his mid 70s with multiple comorbidities and a history of limited-stage SCLC managed with chemoradiation therapy who enrolls in the DeLLphi-312 trial upon disease recurrence — Dr Chiang (47:20)
Promising Investigational Strategies — Dr Chiang (49:14)

CME information and select publications